PG500 Series Presented at the AACR Annual Meeting in...(ule DrugDiscovery team focused on the de...),Health

Date:4/13/2008

ule Drug Discovery team, focused on the design of semi-synthetic oligosaccharide and glycomimetic inhibitors of carbohydrate-protein interactions. The 500 series is the second product line from this research area already showing promising pre-clinical anti-tumor activity.
Progen Information: Linton Burns Progen Pharmaceuticals Limited T: +61 7 3842 3333 E: lintonb@progen-pharma.com Media and Investor Relations: Cindy Ingram Progen Pharmaceuticals Limited T: +61 7 3842 3333 E: cindyi@progen-pharma.com

This press release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties, including without limitation, risks associated with drug development and manufacture, risks inherent in the extensive regulatory approval process mandated by the United States Food and Drug Administration and the Australian Therapeutic Goods Administration, delays in obtaining the necessary approvals for clinical testing, patient recruitment, delays in the conduct of clinical trials, market acceptance of PI-88, PI-166 and other drugs, future capital needs, general economic conditions, and other risks and uncertainties detailed from time to time in the Company's filings with the Australian Securities Exchange and the United States Securities and Exchange Commission. Moreover, there can be no assurance that others will not independently develop similar products or processes or design around patents owned or licensed by the Company, or that patents owned or licensed by the Company will provide meaningful protection or competitive advantages.

'/>"/>

SOURCE Progen Pharmaceuticals Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. BioVascular Inc. Closes $10.87 Million Series C Financing
2. Globus Medical Raises $110 Million in Series E Financing Round
3. Research Presented at ISHLT Shows Promise of Addressing Critical Organ Shortage and Better Organ Preservation
4. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
5. Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings
6. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
7. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
10. New Clinical Studies Presented at the 14th World Congress of Anesthesiology Demonstrate Masimo Advancements in Patient Care
11. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting